Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery
Nucleic Acids Research · 06.01.2025 · 53 (D1) · D1467-D1475
DOI: 10.1093/nar/gkae1128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 06.12.2024. Verfasst von Annalisa Buniello und 31 weiteren Autor:innen. Beteiligte Einrichtung: Open Targets, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK. Hauptthemen laut MEDLINE: Drug Discovery. Die Arbeit wurde bisher 301-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Open Targets.
Abstract (Originalsprache)
The Open Targets Platform (https://platform.opentargets.org) is a unique, open-source, publicly-available knowledge base providing data and tooling for systematic drug target identification, annotation, and prioritisation. Since our last report, we have expanded the scope of the Platform through a number of significant enhancements and data updates, with the aim to enable our users to formulate more flexible and impactful therapeutic hypotheses. In this context, we have completely revamped our target–disease associations page with more interactive facets and built-in functionalities to empower users with additional control over their experience using the Platform, and added a new Target Prioritisation view. This enables users to prioritise targets based upon clinical precedence, tractability, doability and safety attributes. We have also implemented a direction of effect assessment for eight sources of target–disease association evidence, showing the effect of genetic variation on the function of a target is associated with risk or protection for a trait to inform on potential mechanisms of modulation suitable for disease treatment. These enhancements and the introduction of new back and front-end technologies to support them have increased the impact and usability of our resource within the drug discovery community.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Open Targets, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK.
- European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK.
- AstraZeneca UK Limited.
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK.
ORCID-Profile: Annalisa Buniello, Manuel Bernal Llinares, Ian Dunham, Ellen M McDonagh, David Ochoa
Förderung
- Wellcome Trust
- Open Targets
Zitieren
APA
Buniello, A., Suveges, D., Cruz-Castillo, C., Llinares, M. B., Cornu, H., Lopez, I., Tsukanov, K., Roldán-Romero, J. M., Mehta, C., Fumis, L., McNeill, G., Hayhurst, J. D., Martinez Osorio, R. E., Barkhordari, E., Ferrer, J., Carmona, M., Uniyal, P., Falaguera, M. J., Rusina, P., …, & Ochoa, D. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research, 53(D1), D1467-D1475. https://doi.org/10.1093/nar/gkae1128
Vancouver
Buniello A, Suveges D, Cruz-Castillo C, Llinares MB, Cornu H, Lopez I, et al. Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research. 2025;53(D1):D1467-D1475. doi:10.1093/nar/gkae1128
BibTeX
@article{Buniello2025,
author = {Buniello, Annalisa and Suveges, Daniel and Cruz-Castillo, Carlos and Llinares, Manuel Bernal and Cornu, Helena and Lopez, Irene and Tsukanov, Kirill and Roldán-Romero, Juan María and Mehta, Chintan and Fumis, Luca and McNeill, Graham and Hayhurst, James D and Martinez Osorio, Ricardo Esteban and Barkhordari, Ehsan and Ferrer, Javier and Carmona, Miguel and Uniyal, Prashant and Falaguera, Maria J and Rusina, Polina and Smit, Ines and Schwartzentruber, Jeremy and Alegbe, Tobi and Ho, Vivien W and Considine, Daniel and Ge, Xiangyu and Szyszkowski, Szymon and Tsepilov, Yakov and Ghoussaini, Maya and Dunham, Ian and Hulcoop, David G and McDonagh, Ellen M and Ochoa, David},
title = {Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery},
journal = {Nucleic Acids Research},
year = {2025},
volume = {53},
number = {D1},
pages = {D1467--D1475},
doi = {10.1093/nar/gkae1128}
}
EUVIMED